Pharma feed

AbbVie Inc
Abbvie· 25 Apr 2019

AbbVie to Host First-Quarter 2019 Earnings Conference Call

AbbVie to Host First-Quarter 2019 Earnings Conference Call 04/25/19 8:00 am CDT Webcast Presentation Click here for webcast

  • AbbVie Inc
  • Financial and Business Performance
  • Events
  • Company Websites
Central Care Cancer Center
Cccancer· 25 Apr 2019

Central Care’s Dr. Leo Shunyakov Offers Presentation on April 13 in Garden City

Free Bristol-Myers Squibb Presentation and Breakfast Offered Prior to Spring Health Symposium. Central Care Cancer Center’s Dr. Leonid Shunyakov will provide a free presentation focusing on a product manufactured by Bristol-Myers Squibb. The free presentation will take place at Heartland Cancer Center, 410 E.

  • Central Care Cancer Center
  • Bristol-Myers Squibb Co
  • Events
  • Press Releases
  • Company Websites
N
Bayer AG
Reuters· 25 Apr 2019

Bayer gets Monsanto profit boost but legal burden mounts

FRANKFURT (Reuters) - German drug and farming supplies company Bayer posted a 45 percent gain in quarterly core earnings thanks to the acquisition of seed maker Monsanto, while the legal burden it took on with the deal mounted.

  • Bayer AG
  • Monsanto Company
  • Financial and Business Performance
  • New Offerings
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 25 Apr 2019

Novartis lifts annual profit outlook as Cosentyx, Entresto lead first-quarter sales growth

Headline results for the first quarter: Innovative medicines sales $8.8 billion +5% Sandoz sales $2.3 billion -8% Overall revenue $11.1 billion (forecasts of $10.9 billion) +2% Profit $1.9 billion -5% Note: All changes are versus

  • Sandoz Inc
  • Novartis AG
  • Financial and Business Performance
  • New Offerings
  • News Articles
  • News and Other Websites
N
Bayer AG
FirstWord Pharma· 25 Apr 2019

Delhi High Court allows Alembic, Natco to export Bayer drug for specific purposes

Delhi High Court allows Alembic, Natco to export Bayer drug for specific purposes

  • Bayer AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Novartis AG
Seeking Alpha· 25 Apr 2019

Novartis (NVS) CEO Vasant Narasimhan on Q1 2019 Results - Earnings Call Transcript

Novartis (NYSE:NVS) Q1 2019 Earnings Conference Call April 24, 2019 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Offier Shannon Klinger - Legal Counsel Susanne Schaffert

  • Novartis AG
  • Financial and Business Performance
  • New Offerings
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Law 360· 25 Apr 2019

Philly Jury Slams J&J With $120M Award In Mesh Injury Case

By Matt Fair Law360, Philadelphia (April 24, 2019, 4:48 PM EDT) -- A Philadelphia jury hammered a Johnson & Johnson unit with $120 million in damages Wednesday after agreeing that a negligently designed pelvic mesh

  • Johnson & Johnson
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
GlaxoSmithKline PLC
Missoula Current· 25 Apr 2019

GSK in Hamilton invests $100M to expand manufacturing ~ Missoula Current

(KPAX) GlaxoSmithKline announced $100 million of new investment in its manufacturing site in Hamilton. The expansion will expand the production capacity of key components of the adjuvant system used in several of GSK’s vaccines, including their Shingles vaccine, SHINGRIX, which was approved by the US Food and Drug Administration in October 2017.

  • GlaxoSmithKline PLC
  • Business Expansion
  • Company Websites
N
Johnson & Johnson
Seeking Alpha· 25 Apr 2019

Biotech News Recap: Arrowhead Pharmaceuticals Makes Encouraging Progress

AbbVie announced FDA approval of SKYRIZI for the treatment of moderate to severe plaque psoriasis (a step in the right direction to address pressure on Humira sales). While the HBV-deal with Johnson & Johnson was quite lucrative, the substantial potential remains to be realized with the company's varied pipeline.

  • Johnson & Johnson
  • Arrowhead Pharmaceuticals
  • Procurement and Sales
  • New Offerings
  • News Articles
  • News and Other Websites
N
Bayer AG
FirstWord Pharma· 25 Apr 2019

Delhi High Court allows Alembic, Natco to export Bayer drug for specific purposes

Delhi High Court allows Alembic, Natco to export Bayer drug for specific purposes

  • Bayer AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Alexion Pharmaceuticals Inc
Seeking Alpha· 25 Apr 2019

Alexion Pharmaceuticals Q1 Earnings Preview

Alexion Pharmaceuticals (NASDAQ:ALXN) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market open. The consensus EPS Estimate is $2.19 (+30.4% Y/Y) and the consensus Revenue Estimate is $1.13B (+21.4% Y/Y).

  • Alexion Pharmaceuticals Inc
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Bristol-Myers Squibb Co
Seeking Alpha· 25 Apr 2019

Bristol-Myers Squibb Q1 2019 Earnings Preview

Bristol-Myers Squibb (NYSE:BMY) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market open. The consensus EPS Estimate is $1.08 (+14.9% Y/Y) and the consensus Revenue Estimate is $5.72B (+10.2% Y/Y). Over the last 2 years, bmy has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.

  • Bristol-Myers Squibb Co
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Bayer AG
FirstWord Pharma· 25 Apr 2019

Delhi High Court allows Alembic, Natco to export Bayer drug for specific purposes

Delhi High Court allows Alembic, Natco to export Bayer drug for specific purposes

  • Bayer AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Catalent Inc
Catalent· 25 Apr 2019

Technologies To Improve Patient Adherence And Trends In Pharmaceutical Manufacturing To Be Discussed By Catalent At CPhI North America

SOMERSET, N.J. – April 24, 2019 — Catalent (booth 1206), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its experts will participate in two conference sessions at the upcoming CPhI North America tradeshow at the Lakeside Center at McCormick Place, Chicago, on April 30 – May 2, 2019.

  • Catalent Inc
  • Events
  • News Articles
  • News and Other Websites
N
AbbVie Inc
Drug Store News· 25 Apr 2019

AbbVie gets FDA nod for Skyrizi

AbbVie gets FDA nod for Skyrizi Get all the latest industry news in your inbox. AbbVie has received the Food and Drug Administration’s approval for Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

  • AbbVie Inc
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Eli Lilly and Co
Seeking Alpha· 25 Apr 2019

Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity

Eli Lilly (LLY) announced that it had developed a partnership with Avidity Biosciences Incorporated. The reason why is because Eli Lilly wants to tap into Avidity's technology which taps into an interesting mix of antibodies and oligonucleotides.

  • Eli Lilly and Co
  • Avidity Biosciences LLC
  • Partnerships and Alliances
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Bayer AG
Reuters· 24 Apr 2019

Bayer asks California appeals court to throw out $78 million Roundup verdict

(Reuters) - Bayer AG on Wednesday asked a California appellate court to throw out a $78 million judgment it was ordered to pay to a school groundskeeper who claimed the company’s weed killers gave him cancer.

  • Bayer AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
GlaxoSmithKline PLC
Bit (ly)· 24 Apr 2019

Novartis Poaches GSK Veteran as New Sandoz CEO

GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz. Saynor was named the new chief executive officer of the Novartis’ subsidiary on Tuesday. For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines at the U.K.

  • GlaxoSmithKline PLC
  • Sandoz Inc
  • Bitly Inc
  • Management Changes
  • Business Expansion
  • Company Websites
N
Advanced Micro Devices Inc
FirstWord Pharma· 24 Apr 2019

Physician Views snap poll - Asking US ophthalmologists about RTH258, one of Novartis’ key growth drivers in waiting

Novartis recently filed RTH258 - otherwise known as brolucizumab - with the FDA for the treatment of wet age-related macular degeneration (AMD). During the company’s first quarter earnings call on Wednesday, CEO Vas Narasimhan cited RTH258 as one of the biggest potential growth drivers in the late stage pipeline.

  • Advanced Micro Devices Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Advanced Micro Devices Inc
FirstWord Pharma· 24 Apr 2019

Physician Views snap poll - Asking US ophthalmologists about RTH258, one of Novartis’ key growth drivers in waiting

Novartis recently filed RTH258 - otherwise known as brolucizumab - with the FDA for the treatment of wet age-related macular degeneration (AMD). During the company’s first quarter earnings call on Wednesday, CEO Vas Narasimhan cited RTH258 as one of the biggest potential growth drivers in the late stage pipeline.

  • Advanced Micro Devices Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Advanced Micro Devices Inc
FirstWord Pharma· 24 Apr 2019

Physician Views snap poll - Asking US ophthalmologists about RTH258, one of Novartis’ key growth drivers in waiting

Novartis recently filed RTH258 - otherwise known as brolucizumab - with the FDA for the treatment of wet age-related macular degeneration (AMD). During the company’s first quarter earnings call on Wednesday, CEO Vas Narasimhan cited RTH258 as one of the biggest potential growth drivers in the late stage pipeline.

  • Advanced Micro Devices Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Becker's Hospital Review· 24 Apr 2019

Sandoz poaches veteran GlaxoSmithKline exec

Sandoz poaches veteran GlaxoSmithKline exec Richard Saynor, a former GlaxoSmithKline senior executive, was named CEO of Novartis' Sandoz unit April 24, according to Endpoints News. Mr. Saynor has been with GSK for the last nine years.

  • GlaxoSmithKline PLC
  • Sandoz Inc
  • Management Changes
  • News Articles
  • News and Other Websites
N
Advanced Micro Devices Inc
FirstWord Pharma· 24 Apr 2019

Physician Views snap poll - Asking US ophthalmologists about RTH258, one of Novartis’ key growth drivers in waiting

Novartis recently filed RTH258 - otherwise known as brolucizumab - with the FDA for the treatment of wet age-related macular degeneration (AMD). During the company’s first quarter earnings call on Wednesday, CEO Vas Narasimhan cited RTH258 as one of the biggest potential growth drivers in the late stage pipeline.

  • Advanced Micro Devices Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Advanced Micro Devices Inc
FirstWord Pharma· 24 Apr 2019

Physician Views snap poll - Asking US ophthalmologists about RTH258, one of Novartis’ key growth drivers in waiting

Novartis recently filed RTH258 - otherwise known as brolucizumab - with the FDA for the treatment of wet age-related macular degeneration (AMD). During the company’s first quarter earnings call on Wednesday, CEO Vas Narasimhan cited RTH258 as one of the biggest potential growth drivers in the late stage pipeline.

  • Advanced Micro Devices Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
The Philadelphia· 24 Apr 2019

Shingles vaccine production is expanding to meet demand, GSK says

The original shingles vaccine, Merck’s Zostavax, never really caught on after its 2006 debut because it wasn’t very effective, but GSK’s two-shot immunization is extremely popular. Pharmacies in the Philadelphia area and around the country continue to have a hard time keeping it in stock.

  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Business Expansion
  • News Articles
  • News and Other Websites
1 2 3 4 5